|
| Reference | Type of literature | Angiosarcoma type | Treatment | Outcome |
|
| Koontz et al. 2008 [16] | Case reports | (1) Nasal area | (1) Bevacizumab + XRT + SX | (1) CR, 26 mos response duration |
| (2) Nasal area | (2) Bevacizumab + XRT + SX | (2) CR, 8.5 mos response duration |
|
| Gkalpakiotis et al. 2008 [17] | Case report | Well-differentiated exophytic-face | XRT alone
Phase 1: 45 Gy
Phase 2: 20 Gy | 5 yrs remission |
|
| Schlemmer et al. 2008 [18] | Retrospective study | 32 patients | Paclitaxel | 5/8 PR (mean 5.8 mos) |
| 8 scalp and facial | ± Sx | 1/8 CR (42 mos) |
| Rest other sites | ± XRT | 1/8 PD (3 mos) |
| | ± chemotherapy | 1/8 NC (2 mos) |
|
| Nagano et al. 2007 [19] | Retrospective study 9 patients | Cutaneous AS | Docetaxel with or without other previous treatment (XRT, SX) | 6/9: major response (2 CR, 4 PR) |
| 2CR: 2 XRT without SX |
| 4 PR: 1 XRT + SX, 1 XRT without SX, 1 SX without XRT, 1 without SX nor XRT |
|
| Holloway et al. 2005 [20] | Case report | Cutaneous AS (scalp) | Liposomal doxorubicin + XRT | 4 years response duration |
|
| Eiling et al. 2002 [21] | Case report | Cutaneous AS (scalp) | Liposomal doxorubicin + XRT | CR with cervical lymph node metastasis disappearance |
| 4 mos response duration |
|
| Lankester et al. 1999 [22] | Case report | Cutaneous AS (face and scalp) | Liposomal daunorubicin + XRT | 15 mos CR |
|
